Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 156

Sort by

Sort Order Select

Journal Articles

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Hind Al Azzawi, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 1379.

https://doi.org/10.1182/blood-2019-131348

Published: 2019

Journal Articles

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, MD PhD, Seung Tae Lee, MD PhD, Rong Chen, PhD, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD, William Plunkett, PhD

Blood (2019) 134 (Supplement_1): 1761.

https://doi.org/10.1182/blood-2019-128956

Published: 2019

Journal Articles

Adult Hematopoietic Stem and Progenitor Cell Maintenance Requires Histone Variant H3.3 Regulation By Hira

Rebecca Murdaugh, BS, Kevin Hoegenauer, Xiangguo Shi, PhD, Ayumi Kitano, Richard Chapple, PhD, Tianyuan Hu, PhD, Jonathan Tiessen, BS, Daisuke Nakada, PhD

Blood (2019) 134 (Supplement_1): 2473.

https://doi.org/10.1182/blood-2019-131358

Published: 2019

Journal Articles

SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation

Andrew G. Muntean, PhD, James Ropa, Nirmalya SAHA, PhD MSc, BSc, Hsiang-Yu Hu, BS, Justin Serio, Lili Zhao, Venkatesha Basrur, Alexei Nesvizhskii, Ivan Maillard, MD PhD

Blood (2019) 134 (Supplement_1): 110.

https://doi.org/10.1182/blood-2019-122610

Published: 2019

Journal Articles

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 113.

https://doi.org/10.1182/blood-2019-123047

Published: 2019

Journal Articles

Terminal Erythroid Maturation Is Associated with Dynamic Changes in the Abundance of Histone Marks Associated with Active Transcription Elongation and RNA Polymerase II Pausing

Zachary C. Murphy, PhD, Tyler A Couch, BS, Jacquelyn Lillis, MS, Michael Getman, MS, Kimberly Lezon-Geyda, PhD, Vincent P Schulz, PhD, Mohandas Narla, DSc, Patrick G. Gallagher, MD, Laurie A. Steiner, MD

Blood (2019) 134 (Supplement_1): 154.

https://doi.org/10.1182/blood-2019-129561

Published: 2019

Journal Articles

Transcriptional Regulation of Coenzyme Q Biosynthesis By TIF1γ Drives Erythropoiesis

Marlies P. Rossmann, MD PhD, Karen Hoi, Victoria Chan, Julie R. Perlin, PhD, Elliott J. Hagedorn, PhD, Brian J. Abraham, PhD, Song Yang, PhD, Lucas B. Sullivan, PhD, Curtis R. Warren, PhD, Sejal Vyas, PhD, Eugenia Custo-Creig, Bilguujin Dorjsuren, Chad Cowan, PhD, Marcia C. Haigis, PhD, Richard A. Young, PhD, Leonard I Zon, MD

Blood (2019) 134 (Supplement_1): 152.

https://doi.org/10.1182/blood-2019-126833

Published: 2019

Journal Articles

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Milena Mazan, PhD, Marion Chapellier, PhD, Marcus Järås, PhD, Michal Mikula, MD PhD, Eliza Majewska, PhD, Katarzyna Wiklik, PhD, Michal Combik, PhD, Aniela Golas, PhD, Magdalena Masiejczyk, MSc, Elzbieta Fiedor, MSc, Federico Malusa, MSc, Przemyslaw Juszczynski, Prof., MD PhD, Magdalena Cybulska, DVM, Maciej Mikulski, PhD, Jerzy Ostrowski, Prof., MD PhD, Pawel Chrom, MD PhD, Krzysztof Brzózka, PhD, Tomasz Rzymski, PhD

Blood (2019) 134 (Supplement_1): 3774.

https://doi.org/10.1182/blood-2019-128073

Published: 2019

Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 3938.

https://doi.org/10.1182/blood-2019-124072

Published: 2019

Journal Articles

Dysregulation of Splicing Patterns in MDS Induced By the S100A9/Fto Axis

Erika Adriana Eksioglu, MS PhD, Ling Cen, PhD, Xianghong Chen, PhD, Pingyan Cheng, MD, Kenneth Wright, PhD, Thu Le Trinh, PhD, Danielle Gilvary, BS, Wendy Kandell, BS, Jinhong Liu, MD, Yin-Kai Chen, MD, Amy F McLemore, M.S., Alexandra Calescibetta, John Cleveland, PhD, Alan F. List, MD, Sheng Wei, MD

Blood (2019) 134 (Supplement_1): 4215.

https://doi.org/10.1182/blood-2019-128434

Published: 2019

Journal Articles

The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis

Haley Ramsey, PhD MSc, Susu Zhang, Yue Zhao, PhD, Melissa Ann Fischer, PhD, Agnieszka Ewa Gorska, MSc, Maria Arrate, MSc, Londa Fuller, Dalton Greenwood, Matthew C. Stubbs, PhD, Phillip Liu, PhD, Jeffrey C Rathmell, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2018) 132 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2018-99-111393

Published: 2018

Journal Articles

MGP Interacts with BMP-4 and BMP-2 and Supports Normal and Malignant Hematopoietic Stem/Progenitor Cells

Aya Yokoi, Kana Kuronuma, Tomoya Fukuoka, Chie Goto, Miki Matsuo, Eri Adachi, Naoko Okada, Hikaru Tsutsumi, Mirano Kajitani, Natsumi Hasegawa, Shigetaka Asano, MD DSc, Mitsuhiro Ito, MDPhD

Blood (2018) 132 (Supplement 1): 2582.

https://doi.org/10.1182/blood-2018-99-110138

Published: 2018

Journal Articles

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Tammie Yeh, PhD, Greg O'Connor, MS, Justin Cidado, PhD, J. Carl Barrett, PhD

Blood (2018) 132 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2018-99-114948

Published: 2018

Journal Articles

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

Ethika Tyagi, PhD, Clifford Whatcott, PhD, Jason M Foulks, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2018-99-120047

Published: 2018

Journal Articles

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Bradley R Pearse, PhD, Sean M McDonough, MS, Jennifer L Proctor, BS, Rajiv Panwar, PhD, Ganapathy Sarma, PhD, Molly A McShea, MS, Lena Kien, BS, Junia Dushime, BS, Hillary L Adams, MS, Sharon L. Hyzy, MS, Melissa L. Brooks, BS, Rahul Palchaudhuri, PhD, Qing Li, PhD, Nathan M Kallen, BA, Pranoti Sawant, MS, Charlotte F McDonagh, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2018-99-114881

Published: 2018

Journal Articles

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Blood (2018) 132 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2018-99-117167

Published: 2018

Journal Articles

NRF2 Mediates Epigenetic Changes in DNA and Chromatin Structure to Regulate γ-Globin Gene Expression in a Human βYAC Transgenic Mouse Model

Xingguo Zhu, PhD, Alexander H. Ward, PhD, Caixia Xi, PhD, Betty S. Pace, MD

Blood (2018) 132 (Supplement 1): 1053.

https://doi.org/10.1182/blood-2018-99-116438

Published: 2018

Journal Articles

hnRNP U and DDX47 Are Novel FANCD2 Interactors That May Help to Resolve R-Loops during Mild Replication Stress

Yusuke Okamoto, MD, Masako Abe, Akiko Itaya, Junya Tomida, Akifumi Takaori-Kondo, MD PhD, Masato Taoka, Toshiaki Isobe, Minoru Takata, MD PhD

Blood (2018) 132 (Supplement 1): 1301.

https://doi.org/10.1182/blood-2018-99-112364

Published: 2018

Journal Articles

HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p

Ram Kumar Singh, PhD, Richard J. Jones, PhD, Samuel Hong, PhD, Fazal Shirazi, PhD, Hua Wang, PhD, Isere Kuiatse, PhD, Andreas Pahl, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 593.

https://doi.org/10.1182/blood-2018-99-118412

Published: 2018

Journal Articles

Setd2-Mediated Epigenetic Regulation of Erythropoiesis and HSC Maintenance in Mouse Models

Xiaomin Feng, MD PhD, Yile Zhou, MD PhD, Asumi Yokota, PhD, Gang Huang, PhD

Blood (2018) 132 (Supplement 1): 3823.

https://doi.org/10.1182/blood-2018-99-111735

Published: 2018

NARROW

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Adult Hematopoietic Stem and Progenitor Cell Maintenance Requires Histone Variant H3.3 Regulation By Hira

SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Terminal Erythroid Maturation Is Associated with Dynamic Changes in the Abundance of Histone Marks Associated with Active Transcription Elongation and RNA Polymerase II Pausing

Transcriptional Regulation of Coenzyme Q Biosynthesis By TIF1γ Drives Erythropoiesis

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Dysregulation of Splicing Patterns in MDS Induced By the S100A9/Fto Axis

The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis

MGP Interacts with BMP-4 and BMP-2 and Supports Normal and Malignant Hematopoietic Stem/Progenitor Cells

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

NRF2 Mediates Epigenetic Changes in DNA and Chromatin Structure to Regulate γ-Globin Gene Expression in a Human βYAC Transgenic Mouse Model

hnRNP U and DDX47 Are Novel FANCD2 Interactors That May Help to Resolve R-Loops during Mild Replication Stress

HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p

Setd2-Mediated Epigenetic Regulation of Erythropoiesis and HSC Maintenance in Mouse Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only